<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187589</url>
  </required_header>
  <id_info>
    <org_study_id>PLS-02</org_study_id>
    <nct_id>NCT01187589</nct_id>
  </id_info>
  <brief_title>PulseHaler Drug Deposition Study in Chronic Obstructive Pulmonary Disease Patients</brief_title>
  <official_title>Preliminary Assessment of the Effect of PulseHaler™ With Albuterol on Lung Deposition of Aerosol and on Pulmonary Functions in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respinova LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respinova LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at finding the effect of PulseHaler™ with Albuterol on Lung Deposition of
      Aerosol and on Pulmonary Functions in COPD Patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung deposition</measure>
    <time_frame>1 hour</time_frame>
    <description>Lung deposition of the albuterol-containing aerosol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary functions</measure>
    <time_frame>1 hour</time_frame>
    <description>Pulmonary function tests by spirometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>1 hour</time_frame>
    <description>Dyspnea measured by the modified Borg scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Pulsehaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fully operational Pulsehaler, with protocol enabled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulsehaler</intervention_name>
    <arm_group_label>Pulsehaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulizer &amp; Albuterol 0.5ml</intervention_name>
    <description>Albuterol aerosolized by a nebulizer</description>
    <arm_group_label>Pulsehaler</arm_group_label>
    <arm_group_label>Nebulizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), established for at least 1
             year

          -  Post-bronchodilator FEV1/FVC &lt; 0.7

          -  Post-bronchodilator FEV1 in the range 30% - 70% predicted

          -  Age: 40 years or older

          -  Patient signed the informed consent form

        Exclusion Criteria:

          -  Pneumothorax in the past, per anamnesis.

          -  Women at the age of fertility, who are pregnant, or plan pregnancy, or do not use
             contraceptive.

          -  Severe cardiac disease, e.g., Congestive Heart Failure (CHF) grade 3 or higher

          -  Coronary Artery Bypass Graft (CABG) or Acute Myocardial Infarction (MI) within last 3
             months

          -  Other severe systemic disease

          -  Non-cooperative or non-compliant patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Golan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofe Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center Nuclear Medicine Institute</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yuval Avni</name_title>
    <organization>Respinova LTD</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

